PCOS Renamed PMOS in the UK: NHS, NICE and Verity Position (2026)

The Renaming in the UK Context

The May 12, 2026 publication in The Lancet — a British journal — carries particular significance for UK patients. The consensus document, developed over three years by 56 international medical organizations including the Endocrine Society, ESHRE, and the WHO, formally retired the term “Polycystic Ovary Syndrome” in favour of PMOS: Polyendocrine Metabolic Ovarian Syndrome.

The UK's Royal College of Obstetricians and Gynaecologists (RCOG) is expected to issue a formal position statement responding to the renaming, with a timeline projected for Q3–Q4 2026. The RCOG has previously endorsed the Monash International PCOS Guideline 2023, which forms the clinical evidence base now being relabelled under the PMOS terminology.

Why does the name matter for UK patients? Beyond semantics, the terminology used in NHS guidance documents, NICE clinical knowledge summaries (CKS), and RCOG Green-top Guidelines determines how GPs code conditions, how referrals are framed, and whether patients receive appropriate metabolic monitoring. The old name's emphasis on “polycystic” ovaries led to systematic under-recognition of the condition in lean women (20–30% of all cases) and inadequate attention to insulin resistance and cardiovascular risk — both central to the PMOS reframe.

For UK patients right now: nothing has changed clinically. Your PCOS diagnosis is valid, your prescriptions continue, and your NHS entitlements are unaffected. What changes is the conceptual framework your care team will eventually use — and this guide helps you stay ahead of that transition.

NHS Guidance: Where Things Stand

The NHS currently maintains its condition page at nhs.uk/conditions/polycystic-ovary-syndrome-pcos/, which covers symptoms, diagnosis, and treatment for PCOS. As of May 2026, this page has not yet been updated to reflect the PMOS rename. NHS digital content teams typically follow NICE guidance updates rather than leading them, meaning the page is expected to update once NICE publishes revised CKS documentation.

Expected NHS update timeline: Based on NICE's typical review cycle and the anticipated RCOG position statement in Q3–Q4 2026, NHS condition pages and patient-facing resources are most likely to transition to PMOS terminology in early-to-mid 2027. During this transition, both PCOS and PMOS will appear in NHS documents as the older term is phased out.

What UK patients should know now: The NHS overview of PCOS symptoms, tests, and treatments (lifestyle changes, COCs, metformin, clomifene, letrozole) remains entirely accurate and valid under the PMOS framework. Clinical management is unchanged. Use the NHS page alongside the more detailed evidence-based content on this site for a complete picture.

Useful NHS links:

• NHS PCOS condition overview
• NHS PCOS treatment page
• NHS fertility and infertility guidance

NICE Clinical Knowledge Summary: PCOS to PMOS

The NICE Clinical Knowledge Summary (CKS) on Polycystic Ovary Syndrome is the primary reference tool used by UK GPs for diagnosis and management decisions. It is regularly updated and cross-referenced against RCOG Green-top Guidelines and the Monash International PCOS Guideline.

The current CKS remains under the PCOS heading. NICE is expected to begin a formal review process following the RCOG response to the May 2026 consensus. The anticipated update path is:

1. RCOG position statement (Q3–Q4 2026): formal acknowledgement of the PMOS terminology with guidance for UK clinical practice.
2. NICE CKS review initiation (Q4 2026 – Q1 2027): NICE typically initiates a CKS review within 3–6 months of a major specialty society update.
3. Revised CKS publication (2027): updated document using PMOS terminology, with PCOS retained as a recognized synonym throughout the ICD-10 transition period.

GP prescribing implications: Until the CKS is updated, GPs will continue prescribing under PCOS terminology. No changes to prescribing or referral coding are expected during this transition — ICD-10 code E28.2 remains the operative billing code for both PCOS and PMOS. UK patients with PMOS who are seeing their GP for the first time, or who want to discuss the rename, can reference cks.nice.org.uk and note that the underlying Monash 2023 guideline — which NICE CKS already cites — forms the evidence base for the renamed condition.

Verity: The UK PCOS/PMOS Charity

Verity (verity-pcos.org.uk) is the UK's leading patient charity dedicated to PCOS/PMOS. Founded in 1997, Verity provides evidence-based information, peer support networks, and advocacy for women living with the condition across the UK. The charity has been central to raising awareness of diagnostic delays and the under-recognition of PCOS in the UK healthcare system.

Verity's response to the PMOS rename: The charity has acknowledged the May 2026 consensus and is reviewing how to update its resources and branding. Verity has historically been cautious about terminology changes that could confuse patients mid-treatment or disrupt community recognition of the condition. Their guidance to members is consistent with the international consensus position: no clinical changes, no re-diagnosis needed, PCOS remains a valid synonym during the transition.

Verity support resources for UK patients:

• Local support groups: Verity maintains a network of in-person and online support groups across England, Scotland, Wales, and Northern Ireland. Find a group at verity-pcos.org.uk/support.
• Online community: Verity's private Facebook group has over 25,000 UK members and is moderated by trained peer supporters.
• Healthcare professional resources: Verity produces GP-facing information sheets that patients can bring to appointments — particularly useful during the current PMOS transition period.
• Research participation: Verity regularly publicises UK clinical trials and research studies seeking PCOS/PMOS participants.

If you are newly diagnosed or struggling to get a GP referral, contacting Verity is one of the most effective first steps available to UK patients. Their peer support network includes many women who have navigated the NHS referral pathway and can share practical experience.

For UK Patients: What To Do at Your Next GP Appointment

The NHS structure means most UK patients with PMOS will first present to their GP, who will then refer on to an endocrinologist or gynaecologist if needed. Here is a practical guide to navigating that pathway during the PMOS transition period.

How to raise PMOS with your GP

If your GP uses the older PCOS terminology, you do not need to correct them — the terms are clinically identical. However, if you want your records updated or want to discuss the rename, you can say: “I've read that PCOS was renamed PMOS in May 2026 through a consensus published in The Lancet. I'd like my records to reflect the current terminology when NICE updates.”

Referral pathways

Your GP can refer you under NHS to:

• Gynaecologist: for cycle irregularity, fertility concerns, or when first-line GP management (COCs, lifestyle) has not achieved adequate symptom control.
• Endocrinologist: for complex metabolic presentations — significant insulin resistance (HOMA-IR ≥ 3.0), atypical androgen levels, or suspected comorbidities (Cushing, late-onset CAH, thyroid dysfunction).
• Dermatologist: for refractory hormonal acne or female-pattern hair loss not responding to anti-androgenic therapy.

NHS specialist referral: what to request

When requesting a referral, be specific about your primary concern (fertility, metabolic management, skin symptoms). NHS waiting times for outpatient gynaecology and endocrinology vary by ICB (Integrated Care Board) region. If waiting times are long, ask your GP about:

• Enhanced Primary Care — your GP can manage many aspects of PMOS directly with evidence-based protocols
• Any locally commissioned specialist PCOS/PMOS clinics (some NHS trusts run dedicated clinics)
• Referral to a Reproductive Medicine unit if fertility is the primary concern (subject to NICE CG156 eligibility)

Use our GP appointment summary builder to prepare a printable summary of your symptoms, blood test results, and key questions before your appointment.

The Monash International Guideline 2023 in UK Practice

The Monash International PCOS Guideline 2023 — co-developed by Monash University (Australia), ESHRE, and endorsed by RCOG — is the most current evidence-based clinical framework for PMOS management worldwide. NICE CKS already cross-references this guideline. It is the document that informed the May 2026 renaming consensus and provides the clinical foundation for everything that follows under the PMOS name.

NHS adoption: The Monash 2023 guideline recommendations are already reflected in current NHS and NICE PCOS guidance on several key points:

• Letrozole as first-line for ovulation induction (replacing clomifene) — now recommended in NICE CG156 and reflected in many NHS fertility unit protocols following the 2023 update.
• AMH as an alternative to ultrasound for criterion 3 diagnosis — some NHS trusts and private clinics are adopting this, reducing the need for transvaginal ultrasound in adolescents and younger patients.
• Lifestyle and psychological support as first-line interventions — explicitly reinforced in NHS guidance, consistent with Monash 2023's strong emphasis on mental health screening in all PMOS presentations.

Training implications for GPs: The RCOG, working through its trainee and continuing professional development (CPD) programmes, is expected to incorporate PMOS terminology in 2026–2027 training materials. GP training (RCGP) follows NICE guidance and will update curricula accordingly. During the transition period, some GPs will be more aware than others — this guide helps you navigate that variation.

For a detailed breakdown of your diagnostic labs and what each test means in the context of the Monash 2023 recommendations, see our PMOS diagnosis guide and blood tests guide.

Frequently Asked Questions — PMOS in the UK

Will my NHS billing or prescription change because of the PMOS rename?

No. The ICD-10 code E28.2 is unchanged during the transition period (expected through 2028). NHS prescribing, billing, and referral pathways continue under the existing code. No administrative action is required from patients.

Should I ask my GP to update my records from PCOS to PMOS?

It is not medically necessary, but it is reasonable to ask your GP to note "PMOS (formerly PCOS)" in your records. Your existing PCOS diagnosis remains fully valid. No re-diagnosis or new tests are required as a result of the renaming.

Does PMOS change my eligibility for NHS fertility treatment?

No. Eligibility for NHS fertility treatment — including IVF funding under NICE CG156 and CCG/ICB criteria — is determined by clinical criteria, not by the name of the condition. The rename does not affect entitlements under NHS funding frameworks.

What if my GP has never heard of PMOS?

This is expected during the transition period. You can show your GP The Lancet publication from May 12, 2026 or simply explain: "PCOS was officially renamed PMOS in May 2026 by a consensus of 56 international organizations including the WHO." NHS and NICE updates are expected by late 2026 to early 2027. The Verity charity (verity-pcos.org.uk) also provides resources to share with healthcare providers.

Where can UK patients find PMOS support?

Verity (verity-pcos.org.uk) is the UK's dedicated PCOS/PMOS charity. They offer local support groups, an online community, and a helpline. The NHS also lists condition-specific support at nhs.uk/conditions/polycystic-ovary-syndrome-pcos/. For peer support, the Reddit community r/PCOS is active with UK-specific threads.